Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült Államok1. fázis

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

A legfontosabb adatok

Ki végzi
Marker Therapeutics, Inc.
Hol
Aurora, Austin, Denver, Duarte, Kansas City, Madison és New York (Egyesült Államok)Mind a 7 helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
1. fázis
Résztvevők
79 fő, tervezett
Kezdés
2023. jan. 2.
Várható befejezés
2028. febr. 28.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • MT-601
A regiszteradat frissítve
2026. szeptember 15.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat olyan felnőtteket keres, akiknek a limfómája (non-Hodgkin vagy Hodgkin) kiújult, vagy nem reagált a korábbi kezelésre. Az MT-601 nevű, saját sejtjeikből készült T-sejt-terápiát kapják.

Életkor
18 és 100 év között
Nem
Mindkét nem
A betegség stádiuma
Igazolt non-Hodgkin-limfóma, Hodgkin-limfóma vagy CLL, amely kiújult vagy nem reagált a kezelésre. A képalkotó vizsgálaton mérhetőnek kell lennie. Az altípusok közé tartozik a nagy B-sejtes limfóma, az FL, az MCL, az MZL és a HL.
Korábbi kezelés
Legalább 2 korábbi kezelés, vagy a standard kezelések nem alkalmazhatók. Az LBCL-es, FL-es vagy MCL-es betegeknek kaptak már CD19-irányított CAR T-sejt-terápiát, vagy elutasították, illetve nem kaphatták meg. A közelmúltbeli kezeléseket, például a kemoterápiát, a bispecifikus antitesteket vagy a transzplantációt meghatározott ideje be kellett fejezni.

A részvétel fő kizáró okai

  • Ismert HIV-fertőzés vagy aktív hepatitis B vagy C
  • Nagy, terjedelmes daganat a kondicionáló kezelés idején, vagy kezeletlen vagy kezelés alatt álló központi idegrendszeri limfóma
  • Súlyos vagy nem kontrollált autoimmun betegség, vagy elsődleges immunhiány
  • Másik daganat az elmúlt 3 évben, kivéve néhány bőrdaganatot és a carcinoma in situt
  • Terhesség vagy szoptatás

A regiszter feltételei, szó szerint

Mind a 47 feltétel megnézéseKevesebb

Ki vehet részt

  • All applicable inclusion and exclusion criteria must be met at Screening and at Baseline (re-assessment of eligibility within 14 days prior to group assignment); Participants are eligible to be included in the study only if all of the following criteria apply and the participant, in the judgement of the Investigator, is an appropriate candidate for experimental therapy:; General:
  • Participant must be ≥ 18 years of age and capable of giving signed informed consent (ICF), which includes compliance with the requirements and restrictions listed in the ICF and in the protocol, at the time of signing the ICF; Disease Specific:
  • Cytologically or histologically confirmed diagnosis of NHL, HL or CLL based on the 2022 World Health Organization (WHO) criteria for hematolymphoid neoplasms
  • Enrollment of the following subtypes will be eligible:; LBCL including diffuse large B cell lymphoma, primary mediastinal B cell lymphoma (PMBCL), high grade B cell lymphoma (HGBL), T cell rich B cell lymphoma and transformed indolent lymphoma (transformed iNHL); FL; MCL; MZL; HL; The following additional subtypes may be enrolled in disease specific cohorts during Dose Expansion (upon approval by Sponsor); CLL/SLL; CNS lymphoma; CAR T cell refractory
  • Must have measurable disease as per 2014 Lugano criteria or 2018 iwCLL criteria. Participants with splenic MZL must have measurable splenomegaly on imaging or evidence of bone marrow involvement; Prior Treatments
  • Participants who are R/R, are intolerant to, or are considered ineligible for systemic standard of care anticancer treatments, including at least 2 prior therapies. Participants who refuse standard of care treatments may also be considered if documentation is provided that he/she has been made aware of all therapeutic options
  • For participants with LBCL, FL, and MCL: Have received CD19-directed CAR T cell therapy and relapsed ≥ 30 days or attained an incomplete response as the best response within 1 year after CAR T cell administration. Participants who refuse or are ineligible for CAR T cell therapy are eligible for this study. Note: during Dose Expansion, a specific cohort may be enrolled to evaluate participants who were refractory to CD19-directed CAR T cell therapy; Health Status
  • Karnofsky score of ≥70 or performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale
  • Life expectancy ≥12 weeks
  • Adequate blood, liver, renal and cardiac function:; Hematology: Hemoglobin ≥ 7.0 g/dL (can be transfused), absolute lymphocyte count (ALC) ≥ 300/μL, (prior to apheresis only), absolute neutrophil count (ANC) ≥ 750/μL and platelet count ≥ 50,000/μL (prior to the conditioning regimen only); Liver: Bilirubin ≤ 1.5X upper limit of normal (ULN) (exception of bilirubin elevation due to Gilbert's syndrome 3X); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3X ULN; Renal: Serum creatinine ≤ 1.5X ULN or measured or calculated creatinine clearance ≥ 50 mL/min (prior to the conditioning regimen); Cardiac: left ventricular ejection fraction ≥ 45% (prior to the leukapheresis) Sex
  • Female: Is a woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective (i.e., with a failure rate of < 1% per year), preferably with low user dependency during the intervention period and for at least 6 months after the last infusion of MT-601 and agrees not to donate eggs (i.e., ova and oocytes) for the purpose of reproduction during this period
  • Male participants are eligible to participate if they agree to the following during the intervention period and for at least 6 months after the last infusion of MT-601:; Refrain from donating sperm; PLUS either:; Be abstinent from intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR Must agree to use a male condom AND should also be advised of the benefit for a nonpregnant female partner to use a highly effective method of contraception as a condom may break or leak

Ki nem vehet részt

  • Unresolved immune effector cell-associated neurotoxicity syndrome (ICANS) from prior CAR T cell administration. Consideration for Grade 1 may be made after discussion with the Medical Monitor
  • Cardiac conditions:; Medically uncontrolled hypertension (≥ 160 mmHg systolic blood pressure or ≥ 100 mmHg diastolic blood pressure); Congestive heart failure Class ≥ II as defined by the New York Heart Association; Acute coronary syndrome (including unstable angina, coronary artery stenting, or angioplasty, bypass grafting within prior 6 months); History or evidence of current, uncontrolled, clinically significant, unstable arrhythmias
  • Receipt of allogeneic hematopoietic cell transplant (HCT) within 12 months; on immunosuppression or with evidence of donor/mixed chimera
  • Treatment with CD19-directed CAR T cell therapy within 3 months
  • Treatment with bispecific antibody within 1 month
  • Treatment with antibody drug conjugates (ADC's) or PD-1/PD-L1 within 21 days
  • Treatment with monoclonal antibodies impacting T cell function within 14 days
  • Treatment with systemic immunosuppression including systemic corticosteroids (unless ≤5 mg/day oral prednisone or steroid equivalent) within 14 days
  • Treatment with chemotherapy within 7 days; Prior to the conditioning regimen:
  • Treatment with a live, attenuated vaccine within 4 weeks
  • Treatment with antibody drug conjugates (ADC's) or PD-1/PD-L1 within 21 days
  • Treatment with chemotherapy or biologics/monoclonal antibodies within 14 days
  • Treatment with radiation therapy within 7 days
  • Treatment with a tyrosine kinase inhibitor (TKI) within 7 days or 5 half-lives (whichever is longer) before conditioning regimen
  • Treatment with experimental CAR T cell product unless approved by Medical Monitor
  • Treatment with other cancer therapy including investigational agents that do not fit in the above categories within 14 days
  • Major surgery within 14 days; Other
  • Patients are excluded from the study if any of the following criteria apply:; Disease-related
  • Evidence of bulky disease at the time of the conditioning regimen (≥ 10 cm in diameter for LBCL or HL and > 6 cm for other subtypes)
  • Untreated or ongoing treatment for CNS lymphoma or completed treatment within 2 weeks of apheresis (Note: May be allowed in Dose Expansion if disease specific cohort for CNS lymphoma is opened)
  • Refractory to CAR T therapy defined as a best response of stable disease or disease progression (Note: May be allowed in Dose Expansion if disease specific cohort for CAR T cell therapy refractory is opened)
  • Requirement for urgent therapy due to tumor mass effects such as bowel obstruction or blood vessel compression Medical Conditions
  • Severe or uncontrolled autoimmune disorder
  • History or presence of clinically relevant CNS pathology such as epilepsy, seizure, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis
  • History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, breast, and/or prostate) unless disease free for at least 3 years
  • Participant has known human immunodeficiency virus (HIV) infection, or active hepatitis B virus (HBV)/hepatitis C virus (HCV) infection
  • Acute bacterial, viral, fungal infection requiring systemic therapy (uncomplicated urinary tract infection and bacterial pharyngitis are permitted if responding to therapy)
  • History of severe allergic reactions to any of the study intervention components including conditioning regimen, dimethyl sulfoxide (DMSO) or to tocilizumab
  • Clinically significant reversible toxicities from prior cancer therapy that have not recovered to Grade 1 or baseline; Participants with Grade 2 neuropathies due to prior treatment will be allowed on study; Participants with clinical nonsignificant toxicities, such as alopecia, will be allowed on study; Prior/Concomitant Therapy; Prior to Apheresis:
  • Primary immunodeficiency
  • Oxygen saturation at room air < 92%
  • Receipt of autologous HCT within 3 months
  • Hematopoietic growth factors <2 days; At either time:
  • Pregnant or lactating
  • Any other issue which, in the opinion of the treating physician, would make the participant ineligible for the study

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 100 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • University of ColoradoAurora, Egyesült ÁllamokContact: Manali Kamdar, MDRésztvevőt keres
  • Sarah Cannon Research Institute at St. David's South AustinAustin, Egyesült ÁllamokContact: Aravind Ramakrishnan, MDRésztvevőt keres
  • Colorado Blood Cancer Institute (Sarah Cannon)Denver, Egyesült ÁllamokContact: Luke Mountjoy, DORésztvevőt keres
  • City of HopeDuarte, Egyesült ÁllamokContact: Geoffrey Shouse, DO, PhDRésztvevőt keres
  • University of Kansas Medical CenterKansas City, Egyesült ÁllamokContact: Cari StockardRésztvevőt keres
  • University of Wisconsin Carbone Cancer CenterMadison, Egyesült ÁllamokContact: Mariah EndresRésztvevőt keres
  • CornellNew York, Egyesült ÁllamokContact: Nicole SantosRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing).

A vizsgálat csoportja

  • Single Arm StudyA vizsgált kezelés

    Single arm study evaluating MT-601 investigational product at 200 million cells and 400 million cells per dose

    Kezelés: MT-601

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients With Relapsed or Refractory Non-Hodgkin and Hodgkin Lymphoma (APOLLO)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
Kérdések a feltételekről
Forrás: NCT05798897: ki vehet részt
A regiszteradat frissítve
2026. szeptember 15.